Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-28T02:20:01.893Z Has data issue: false hasContentIssue false

Characterization of a novel antibacterial agent that inhibits bacterial translation

Published online by Cambridge University Press:  06 September 2002

NINA BÖDDEKER
Affiliation:
Gilead Sciences, Foster City, California 94404, USA
GINA BAHADOR
Affiliation:
Gilead Sciences, Foster City, California 94404, USA
CRAIG GIBBS
Affiliation:
Gilead Sciences, Foster City, California 94404, USA
ERIC MABERY
Affiliation:
Gilead Sciences, Foster City, California 94404, USA
JOHN WOLF
Affiliation:
Gilead Sciences, Foster City, California 94404, USA
LIANHONG XU
Affiliation:
Gilead Sciences, Foster City, California 94404, USA
JULIA WATSON
Affiliation:
Gilead Sciences, Foster City, California 94404, USA
Get access

Abstract

Bacterial protein synthesis is the target for several classes of established antibiotics. This report describes the characterization of a novel translation inhibitor produced by the soil bacterium Flexibacter. The dipeptide antibiotic TAN1057 A/B was synthesized and designated GS7128. As reported previously, TAN1057 inhibits protein synthesis in both Escherichia coli and Staphylococcus aureus, leaving transcription unaffected. Cell-free translation systems from E. coli were used to further dissect the mechanism of translational inhibition. Binding of mRNA to ribosomes was unaffected by the drug, whereas the initiation reaction was reduced. Elongation of translation was completely inhibited by GS7128. Detailed analysis showed that the peptidyl transferase reaction was strongly inhibited, whereas tRNA binding to both A- and P-site was unaffected. Selection and analysis of drug-resistant mutants of S. aureus suggests that drug uptake may be mediated by a dipeptide transport mechanism.

Type
Research Article
Information
RNA , Volume 8 , Issue 9 , September 2002 , pp. 1120 - 1128
Copyright
2002 RNA Society

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)